What is the role of ¹⁸F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?

References

• Romaguera J E, Fayad L, Rodriguez M A, Broglio K R, Hagemeister F B, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984–1992
   PubMed Web of Science ®Google Scholar
• Ritchie D S, Seymour J F, Grigg A P, Roberts A W, Hoyt R, Thompson S, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Haematol 2007; 86: 101–105
   PubMed Web of Science ®Google Scholar
• Vose J, Loberiza P, Bierman G, Bociek J, Armitage J. Mantle cell lymphoma (MCL): induction therapy with HyperCVAD/High-dose methotrexate and cytarabine (M-C) (±rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol 2006; 24(Suppl 18), (Abstr. 7511)
   PubMed Web of Science ®Google Scholar
• Gill S, Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 2008; 49: 398–409
   PubMed Web of Science ®Google Scholar
• Juweid M E, Wiseman G A, Vose J M, Ritchie J M, Menda Y, Wooldridge J E, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652–4661
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, Pedersen L M, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52–59
   PubMed Web of Science ®Google Scholar
• Ng A P, Wirth A, Seymour J F, Lee M, Hogg A, Januszewicz H, et al. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma 2007; 48: 596–600
   PubMed Web of Science ®Google Scholar
• Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
   PubMed Web of Science ®Google Scholar
• MacManus M P, Seymour J F, Hicks R J. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 2007; 7: 10–18
   PubMedGoogle Scholar
• Gill S, Wolf M, Prince H M, Januszewicz H, Ritchie D, Hicks R J, et al. 18F-fluorodeoxyglucose positron emission tomography for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymph Myeloma 2008; 8: 159–165
   PubMedGoogle Scholar
• Karam M, Matthew W, Shet N, Ata A. FDG PET study may identify mantle cell lymphoma patients with an unusually favourable prognosis. J Nucl Med 2007; 48(Suppl 2), (Abstr. 148P)
   Google Scholar
• Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio J A, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875–3876
   PubMed Web of Science ®Google Scholar
• Brepoels L, Stroobants S, De Wever W, Dierickx D, Vandenberghe P, Thomas J, et al. Positron emission tomography (PET) in mantle cell lymphoma. Leuk Lymphoma 2008; 49: 1693–1701
   PubMed Web of Science ®Google Scholar
• Leitch H A, Gascoyne R D, Chhanabhai M, Voss N J, Klasa R, Connors J M. Limited-stage mantle-cell lymphoma. Ann Oncol 2003; 14: 1555–1561
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Seymour J F, Fuller L, Cabanillas F. Combined modality therapy for stage I-II MALT lymphoma and mantle cell lymphoma. Ann Oncol 1996; 7: 211–213
   PubMed Web of Science ®Google Scholar
• Romaguera J E, Medeiros L J, Hagemeister F B, Fayad L E, Rodriguez M A, Pro B, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97: 586–591
   PubMed Web of Science ®Google Scholar
• Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi Y E, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 4643–4651
   PubMed Web of Science ®Google Scholar
• Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571–578
   PubMed Web of Science ®Google Scholar
• Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutierrez G, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19: 135–141
   PubMed Web of Science ®Google Scholar
• Gill S, Prince H M, Wolf M M, Wirth A, Ryan G, Carney D, et al. Mantle cell lymphoma with central nervous involvement: frequency and clinical features. Ann Oncol 2008; 19(Suppl 4)iv83, (Abstr. 438)
   Google Scholar
• Lapela M, Leskinen S, Minn H R, Lindholm P, Klemi P J, Soderstrom K O, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522–3527
   PubMed Web of Science ®Google Scholar
• Determann O, Hoster E, Ott G, Wolfram B H, Loddenkemper C, Hansmann L M, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111: 2385–2387
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, Chan W C, Connors J M, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185–197
   PubMed Web of Science ®Google Scholar
• Katzenberger T, Petzoldt C, Holler S, Mader U, Kalla J, Adam P, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006; 107: 3407
   PubMed Web of Science ®Google Scholar
• Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006; 107: 2271–2278
   PubMed Web of Science ®Google Scholar
• Zelenetz A D, Persky D, Rice R D, Maragulia J, Weaver S A, Portlock C S, et al. Results of sequential chemotherapy followed by high dose therapy and autologous stem cell rescue for mantle cell lymphoma: role of rituximab and functional imaging. Ann Oncol 2008; 19(Suppl 4)iv83, (Abstr. 013)
   Google Scholar